Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B, Uprichard M, Nemunaitis J. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Clin Oncol (R Coll Radiol) 2009;
21:464-72. [PMID:
19501491 DOI:
10.1016/j.clon.2009.04.007]
[Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2008] [Revised: 04/01/2009] [Accepted: 04/28/2009] [Indexed: 10/20/2022]
Abstract
AIMS
Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat mesilate (PT-100) is an orally available amino boronic dipeptide that specifically inhibits dipeptidyl peptidases (including fibroblast activation protein) and enhances an immune response. The aim of this study was to determine the efficacy and safety of talabostat in NSCLC patients.
MATERIALS AND METHODS
A phase II trial was conducted to evaluate talabostat in combination with docetaxel in patients with advanced NSCLC after failure of previous platinum-based chemotherapy. In total, 42 patients were enrolled.
RESULTS
Talabostat was well tolerated. Two patients achieved a partial response and one achieved a complete response.
CONCLUSION
There was no evidence that talabostat enhanced the clinical activity of docetaxel in patients with NSCLC.
Collapse